Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry

Proteomics

Volumn 8, Issue 8, 2008, Pages 1576-1585

  Stoop, Marcel P ^a   Dekker, Lennard J ^a   Titulaer, Mark K ^a   Burgers, Peter C ^a   Smitt, Peter A E Sillevis ^a   Luider, Theo M ^a   Hintzen, Rogier Q ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cerebrospinal fluid; Differentially expressed peptides; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN D; CHROMOGRANIN A; CLUSTERIN; COMPLEMENT COMPONENT C3;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DATA ANALYSIS; DEGENERATIVE DISEASE; DEMYELINATION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; CEREBROSPINAL FLUID PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PEPTIDE MAPPING; PROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYNDROME;

EID: 42549094545     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700446     Document Type: Article

References (40)

1. Keegan, B. M., Noseworthy, J. H., Multiple sclerosis. Annu. Rev. Med. 2002, 53, 285-302.
2. Compston, A., Coles, A., Multiple sclerosis. The Lancet 2002, 359, 1221-1231.
3. Bielekova, B., Martin, R., Development of biomarkers in multiple sclerosis. Brain 2004, 127, 1463-1478.
4. Yuan, X., Desiderio, D. M., Proteomics analysis of pre-fractionated lumbar cerebrospinal fluid. Proteomics 2005, 5, 541-550.
5. Romeo, M. J., Espina, V., Lowenthal, M., Espina, B. H. et al., CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2005, 2, 57-70.
6. Greenstein, J. I., Current concepts of the cellular and molecular pathophysiology of multiple sclerosis. Dev. Neurobiol. 2007, 67, 1248-1265.
7. Tintore, M., Early MS treatment. Int. MS J. 2007, 14, 5-10.
8. Irani, D. N., Andersen, C., Gundry, R., Cotter, R. et al., Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006, 26, 237-247.
9. Del Boccio, P., Pieragostino, D., Lugaresi, A., Di Ioia, M. et al., Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 2007, 62, 201-204.
10. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2005, 5, 1647-57.
11. Hammack, B. N., Owens, G. P., Burgoon, M. P., Gilden, D. H., Improved resolution of human cerebrospinal fluid proteins on two-dimensional gels. Mult. Scler. 2003, 9, 472-475.
12. Dekker, L. J., Boogerd, W., Stockhammer, G., Dalebout, J. et al., MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 2005, 4, 1341-1349.
13. Dekker, L. J., Dalebout, J. C., Siccama, I., Jenster, G. et al., A new method to analyze matrix-assisted laser desorption/ ionization time-of-flight peptide profiling mass spectra. Rapid Commun. Mass Spectrom. 2005, 19, 865-870.
14. Gaddis, G. M., Gaddis, M. L., Introduction to biostatistics: Part 5, Statistical inference techniques for hypothesis testing with nonparametric data. Ann. Emerg. Med. 1990, 19, 1054-1059.
15. Titulaer, M. K., Siccama, I., Dekker, L. J., van Rijswijk, A. L. et al., A database application for pre-processing, storage and comparison of mass spectra derived from patients and controls. BMC Bioinformatics 2006, 7, 403.
16. Tintoré, M., Rovira, A., Rio, J., Nos, C. et al., Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann. Neurol. 2005, 57, 210-215.
17. Brück, W., Stadelmann, C., Inflammation and neurodegeneration in multiple sclerosis. Neurol. Sci. 2003, 24, 265-267.
18. McDonald, W. I., Compston, A., Edan, G., Goodkin, D. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121-127.
19. Miller, D., Barkhof, F., Montalban, X., Thompson, A. et al., Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005, 4, 281-288.
20. Fernando, K. T. M., Tozer, D. J., Miszkiel, K. A., Gordon, R. M. et al., Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005, 128, 2911-2925.
21. Prat, A., Antel, J., Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 2005, 18, 225-230.
22. Bjartmar, C., Trapp, B. D., Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 2001, 14, 271-278.
23. Zamvil, S. S., Steinman, L., Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 2003, 38, 685-688.
24. Coles, A. J., Wing, M. G., Molyneux, P., Paolillo, A. et al., Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999, 46, 296-304.
25. Zeman, A. Z., Kidd, D., McLean, B. N., Kelly, M. A. et al., A study of oligoclonal band negative multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1996, 60, 27-30.
26. Aivado, M., Spentzos, D., Alterovitz, G., Otu, H. H. et al., Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin. Chem. Lab. Med. 2005, 43, 133-140.
27. You, J. S., Gelfnova, V., Knierman, M. D., Witzmann, F. A. et al., The impact of blood contamination of cerebrospinal fluid. Proteomics 2005, 5, 290-296.
28. Ramström, M., Hagman, C., Mitchell, J. K., Derrick, P. J. et al., Depletion of high-abundant proteins in body fluids prior to liquid chromatography fourier transform ion cyclotron resonance mass spectrometry. J. Proteome Res. 2005, 4, 410-416.
29. Dumont, D., Noben, J. P., Raus, J., Stinissen, P. et al., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
30. Hammack, B. N., Kung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
31. Kirkpatrick, L. L., Matzuk, M. M., Dodds, D. D., Perin, M. S., Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J. Biol. Chem. 2000, 275, 11786-11792.
32. Stabach, P. R., Morrow, J. S., Identification and characterization of beta V spectrin, a mammalian ortholog of Drosophila beta H spectrin. J. Biol. Chem. 2000, 275, 21385-21395.
33. Reindl, M., Knipping, G., Wicher, I., Dilitz, E. et al., Increased intrathecal production of apolipoprotein D in multiple sclerosis. J. Neuroimmunol. 2001, 119, 327-332.
34. Mar, P., Gradl, T., Dorner, C., Contag, I., A longitudinal srudy of immunological parameters in multiple sclerosis: Cell-mediated immunity and complement profiles. Clin. Exp. Immonol. 1979, 36, 442-448.
35. Williams, K. C., Ulvestad, E., Hickey, W. F., Immunology of multiple sclerosis. Clin. Neurosci. 1994, 2, 229-245.
36. Li, W., Trovero, F., Cordier, J., Wang, Y. et al., Prenatal exposure of rats to Ginkgo biloba extract (EGgb 761) increases neuronal survival/growth and alters gene expression in the developing fetal hippocampus. Brain Res. Dev. Brain Res. 2003, 144, 169-180.
37. Polihronis, M., Paizis, K., Carter, G., Sedal, L. et al., Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. J. Neurol. Sci. 1993, 115, 230-233.
38. Zipp, F., Aktas, O., The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29, 518-527.
39. Taylor, D. L., Diemel, L. T., Cuzner, M. L., Pocock, J. M., Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J. Neurochem. 2002, 85, 1179-1191.
40. Lechner, T., Adlassnig, C., Humpel, C., Kaufmann, W. A. et al., Chromogranin peptides in Alzheimer's disease. Exp. Gerontol. 2004, 39, 101-113.